Literature DB >> 20228696

Administration of human recombinant bone morphogenetic protein-2 for spine fusion may be associated with transient postoperative renal insufficiency.

Jonathan M Latzman1, Li Kong, Chuanju Liu, Uzma Samadani.   

Abstract

STUDY
DESIGN: Retrospective chart review.
OBJECTIVE: We reviewed the peri- and postoperative outcomes of our patients who had undergone lumbar and lumbosacral fusion both with and without recombinant human bone morphogenetic protein (rhBMP) over a period of 8 years to assess the frequency of complications and new diagnoses associated with the use of rhBMP2. SUMMARY OF BACKGROUND DATA: Administration of rhBMP2 for augmentation of lumbar and lumbosacral spinal fusion has not previously been associated with systemic complications.
METHODS: A review of all patients undergoing lumbar and lumbosacral fusion over an 8-year period was performed to determine the frequency of postoperative complications and new diagnoses. Comparisons in complication frequency and new postoperative diagnoses between patients receiving rhBMP2 versus only allo- or autograft were made. Statistical methodology was applied to determine significance. RESULTS.: None of the 105 patients not receiving rhBMP2 and 3 of 24 patients receiving rhBMP2 had blood urea nitrogens and creatinines that more than doubled and reached values >30 and 1.5 mg/dL, respectively, after surgery (P = 0.006). Renal parameters returned to baseline within 45 days of surgery. Two of the 3 patients with postoperative renal insufficiency had been administered 16 mL (24 mg) of rhBMP2, whereas all other patients receiving rhBMP2 had received 8 mL (12 mg). Both of these patients also had supraventricular tachycardia, fever, and mental status changes after surgery. We recorded no significant increase in the incidence of new endocrinologic, autoimmune, neurologic, or neoplastic disorders associated with the use of rhBMP2 in our small patient population.
CONCLUSION: A small subset of patients may develop transient renal insufficiency after rhBMP2 to augment spinal fusion. Higher doses of rhBMP2 may possibly increase the risk of developing renal insufficiency in particular patients; however, additional study is needed before all the risk factors are understood.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20228696     DOI: 10.1097/BRS.0b013e3181c71447

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  12 in total

1.  Trends analysis of rhBMP utilization in single-level posterior lumbar fusion (PLF) in the United States.

Authors:  Lifeng Lao; Jeremiah R Cohen; Elizabeth L Lord; Zorica Buser; Jeffrey C Wang
Journal:  Eur Spine J       Date:  2015-05-24       Impact factor: 3.134

Review 2.  Bone morphogenetic protein use in spine surgery-complications and outcomes: a systematic review.

Authors:  Antonio Faundez; Clément Tournier; Matthieu Garcia; Stéphane Aunoble; Jean-Charles Le Huec
Journal:  Int Orthop       Date:  2016-03-10       Impact factor: 3.075

3.  Complications and cancer rates in spine fusion with recombinant human bone morphogenetic protein-2 (rhBMP-2).

Authors:  Julia Vavken; Alexander Mameghani; Patrick Vavken; Stefan Schaeren
Journal:  Eur Spine J       Date:  2015-03-14       Impact factor: 3.134

4.  The use of rhBMP in spine surgery: is there a cancer risk?

Authors:  John G Devine; Joseph R Dettori; John C France; Erika Brodt; Robert A McGuire
Journal:  Evid Based Spine Care J       Date:  2012-05

5.  Change in Off-Label Use of Bone Morphogenetic Protein in Spine Surgery and Associations with Adverse Outcome.

Authors:  Jashvant Poeran; Mathias Opperer; Rehana Rasul; Madhu Mazumdar; Federico P Girardi; Alexander P Hughes; Stavros G Memtsoudis; Vassilios Vougioukas
Journal:  Global Spine J       Date:  2016-01-15

Review 6.  The role of peptides in bone healing and regeneration: a systematic review.

Authors:  Ippokratis Pountos; Michalis Panteli; Anastasios Lampropoulos; Elena Jones; Giorgio Maria Calori; Peter V Giannoudis
Journal:  BMC Med       Date:  2016-07-11       Impact factor: 8.775

7.  An in vivo Comparison Study Between Strontium Nanoparticles and rhBMP2.

Authors:  Giulia Montagna; Francesco Cristofaro; Lorenzo Fassina; Giovanna Bruni; Lucia Cucca; Alejandro Kochen; Paola Divieti Pajevic; Beth Bragdon; Livia Visai; Louis Gerstenfeld
Journal:  Front Bioeng Biotechnol       Date:  2020-06-16

8.  Activin A/BMP2 Chimera (AB204) Exhibits Better Spinal Bone Fusion Properties than rhBMP2.

Authors:  Dalsung Ryu; Byung-Hak Yoon; Chang-Hyun Oh; Moon-Hang Kim; Ji-Yong Kim; Seung Hwan Yoon; Senyon Choe
Journal:  J Korean Neurosurg Soc       Date:  2018-10-30

9.  Synthetic hydrogel scaffold is an effective vehicle for delivery of INFUSE (rhBMP2) to critical-sized calvaria bone defects in rats.

Authors:  Peter D Mariner; Justin M Wudel; David E Miller; E Erin Genova; Sven-Olrik Streubel; Kristi S Anseth
Journal:  J Orthop Res       Date:  2012-10-15       Impact factor: 3.494

10.  Trends Analysis of rhBMP Utilization in Single-Level Posterior Lumbar Interbody Fusion in the United States.

Authors:  Lifeng Lao; Jeremiah R Cohen; Zorica Buser; Darrel S Brodke; Jim A Youssef; Jong-Beom Park; S Tim Yoon; Jeffrey C Wang; Hans-Joerg Meisel
Journal:  Global Spine J       Date:  2017-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.